What is it about?
Raised serum C-peptide than raised Lp(a) can be a prior predictor for cardiometabolic disease risk in healthy participants and patients with T2DM with increased cardiometabolic biomarkers. Case and control males and females with visceral obesity are exposed to increased C-peptide.
Featured Image
Photo by Vincent Guth on Unsplash
Why is it important?
Association of C-peptide and lipoprotein (a) as two novel predictors with cardiometabolic biomarkers in patients with type 2 diabetes were demonstrated. Therefore, reducing raised serum C-peptide and Lp(a) levels with strict control of LDL-C together with weight reduction would be the best approach to prevent CAD consequences.
Perspectives
Monitoring of patients with type 2 diabetes and seemingly healthy individuals to prevent CVD consequences such as myocardial infarction is a critical public health issue for the health of the global community.
Mohammad Reza Mahmoodi
Kerman University of Medical Sciences
Read the Original
This page is a summary of: Association of C-peptide and lipoprotein(a) as two predictors with cardiometabolic biomarkers in patients with type 2 diabetes in KERCADR population-based study, PLoS ONE, May 2022, PLOS,
DOI: 10.1371/journal.pone.0268927.
You can read the full text:
Resources
Contributors
The following have contributed to this page
